MY

Myomo IncNYSE-MKT MYO Stock Report

Last reporting period 31 Dec, 2023

Updated 20 Nov, 2024

Last price

Market cap $B

0.112

Micro

Exchange

XASE - Nyse MKT LLC

MYO Stock Analysis

MY

Uncovered

Myomo Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

47/100

Low score

Market cap $B

0.112

Dividend yield

Shares outstanding

20.922 B

Myomo, Inc. is a medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The company is headquartered in Boston, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2017-06-12. The firm develops and markets the MyoPro product line. The MyoPro is a myoelectric-controlled upper limb brace (orthosis), which is a rigid brace used for the purpose of supporting a patient's weak or paralyzed arm to enable and help improve functional activities of daily living (ADLs) in the home and community. The MyoPro enables individuals to self-initiate and control movements of a partially paralyzed or weakened limb using their own muscle signals. The Company’s products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury and other neurological disorders. The firm primarily provides its devices directly to patients and bill their insurance companies.

View Section: Eyestock Rating